2. MAPK/ERK Pathway Stem Cell/Wnt Epigenetics Neuronal Signaling Protein Tyrosine Kinase/RTK
  3. ERK Epigenetic Reader Domain Trk Receptor
  4. Polygalasaponin XXXII

Polygalasaponin XXXII is an orally active cognitive enhancer. Polygalasaponin XXXII promotes the phosphorylation of ERK, CREB, Synapsin I and TrkB. Polygalasaponin XXXII enhances basal synaptic transmission. Polygalasaponin XXXII attenuates Scopolamine (HY-N0296)-induced cognitive impairment and improves hippocampus-dependent learning and memory abilities. Polygalasaponin XXXII can be used in research related to cognitive dysfunction.

For research use only. We do not sell to patients.

Polygalasaponin XXXII

Polygalasaponin XXXII Chemical Structure

CAS No. : 176182-04-0

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Polygalasaponin XXXII Related Antibodies

Top Publications Citing Use of Products

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

View All Trk Receptor Isoform Specific Products:

View All Isoforms
TrkA TrkB TrkC Trk

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Polygalasaponin XXXII is an orally active cognitive enhancer. Polygalasaponin XXXII promotes the phosphorylation of ERK, CREB, Synapsin I and TrkB. Polygalasaponin XXXII enhances basal synaptic transmission. Polygalasaponin XXXII attenuates Scopolamine (HY-N0296)-induced cognitive impairment and improves hippocampus-dependent learning and memory abilities. Polygalasaponin XXXII can be used in research related to cognitive dysfunction[1][2][3].

IC50 & Target[1]

TrkB

 

In Vitro

Polygalasaponin XXXII (1 μM; 4 min) rapidly activates phosphorylation of ERK, CREB, and synapsin I in primary rat hippocampal neurons (5 DIV)[1].
Polygalasaponin XXXII protects PC12 cells against serum deficiency-induced damage[3].
Polygalasaponin XXXII protects PC12 cells against Glutamate (HY-W250122)-induced neurotoxicity[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Polygalasaponin XXXII Related Antibodies
In Vivo

Polygalasaponin XXXII (0.125-2 mg/kg; p.o.; once daily; for 16 consecutive days) significantly improves scopolamine (HY-N0296)-induced cognitive impairment in mice, with the 2 mg/kg dose exerting the most prominent molecular and behavioral effects[1].
Polygalasaponin XXXII (400 μM; intracerebroventricular injection; single administration) significantly enhances basal synaptic transmission in the dentate gyrus of anesthetized rats and induces long-term potentiation[1].
Polygalasaponin XXXII (0.125-2 mg/kg; p.o.; once daily; for 19 consecutive days) improves scopolamine (HY-N0296)-induced cognitive impairment in mice, and the 0.5 mg/kg and 2 mg/kg doses significantly enhance the phosphorylation level of TrkB in the hippocampus[3].
Polygalasaponin XXXII (5 μL of 400 μM solution; intracerebroventricular injection; single administration) significantly enhances hippocampal LTP in rats, with its PS amplitude reaching up to 378% of the baseline level[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J (male, 8 weeks old, 18-20 g, scopolamine-induced amnesia)[1]
Dosage: 0.125 mg/kg; 0.5 mg/kg; 2 mg/kg
Administration: p.o.; daily; 16 days
Result: Increased swimming time in the target quadrant during probe trial significantly compared to scopolamine model group.
Shortened scopolamine-prolonged escape latency significantly at 0.125 mg/kg and 2 mg/kg doses; showed a trend toward shorter latency at 0.5 mg/kg dose (P=0.053).
Increased hippocampal ERK phosphorylation significantly compared to both control and model groups at all doses.
Increased hippocampal CREB phosphorylation significantly compared to both control and model groups at 0.5 mg/kg and 2 mg/kg doses; significantly increased CREB phosphorylation compared to model group at 0.125 mg/kg dose.
Reversed scopolamine-induced attenuation of synapsin I phosphorylation significantly at 2 mg/kg dose.
Increased hippocampal BDNF levels significantly compared to model group at all doses; increased BDNF levels compared to control group at 2 mg/kg dose.
Animal Model: Wistar (male, 3 months old, 230-260 g)[1]
Dosage: 1 μmol/L
Administration: i.c.v.; single dose
Result: Increased population spike amplitude to 162% of baseline within 5 min of administration.
Reached population spike amplitudes of 172%, 215%, and 254% of baseline at 10, 30, and 60 min post-administration, respectively.
Induced long-term potentiation in the hippocampal dentate gyrus, as shown by sustained increase of over 30% above baseline for more than 30 min.
Animal Model: C57BL/6J (male, 18-20 g)[3]
Dosage: 5 mg/kg·d-1; 20 mg/kg·d-1
Administration: p.o.; daily; 13 days
Result: Significantly reversed scopolamine-induced increases in channel water maze latency time and error numbers (5 mg/kg dose only).
Demonstrated no significant efficacy relative to the model group (20 mg/kg dose only).
Animal Model: Wistar (male, 3 months old, 230-260 g)[3]
Dosage: 5 μL of 400 μmol/L solution (final brain concentration of 1 μmol/L)
Administration: i.c.v.; single injection
Result: Significantly enhanced HFS-induced LTP compared to the control group.
Increased population spike (PS) amplitudes to 310% within 20 minutes post-injection, and reached 340%, 378%, and 366% at 40, 50, and 55 minutes post-injection, respectively.
Molecular Weight

1675.76

Formula

C79H118O38
CAS No.
SMILES

OC[C@](C([C@]1([H])CC2(C)C)=CC[C@]3([H])[C@]4(C[C@@H]5O)C)(CC[C@]1(CC2)C(O[C@H](O[C@@H]6C)[C@@H]([C@H]([C@H]6OC(/C=C/C(C=C7)=CC=C7OC)=O)O[C@H](O[C@H]8C)[C@@H]([C@@H]([C@H]8O)O)O)O[C@H](O[C@H]9C)[C@@H]([C@@H]([C@H]9O[C@H](OC[C@H]%10O)[C@@H]([C@H]%10O[C@H](OC[C@@H]%11O)[C@@H]([C@H]%11O)O)O)O[C@H](OC[C@](O)%12CO)[C@@H]%12O)O)=O)[C@@]3(CC[C@@]4([H])[C@@](C)([C@H]5O[C@@H]([C@@H]([C@H]%13O)O)O[C@@H]([C@H]%13O)CO)C(O)=O)C
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Polygalasaponin XXXII Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Polygalasaponin XXXII176182-04-0ERKEpigenetic Reader DomainTrk ReceptorExtracellular signal regulated kinasesTropomyosin related kinase receptorCREBPC12 cellssynapsin IBDNFprimary rat hippocampal neuronsdementiaTrkBscopolamine-induced cognitive impairmentMAP kinase cascadeInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Polygalasaponin XXXII
Cat. No.:
HY-N20637
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.